Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Homologous Recombination Deficiency”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT06237205
What this trial is testing

Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency

Who this might be right for
Efficacy
Korea University Anam Hospital 33
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07565155
What this trial is testing

Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency

Who this might be right for
Pancreatic AdenocarcinomaHomologous Recombination Deficiency
Peter Hosein, MD 40
Testing effectiveness (Phase 2)Study completedNCT02401347
What this trial is testing

Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

Who this might be right for
Advanced Breast CancerHER2/Neu NegativeTriple-Negative Breast Cancer
Melinda Telli 21
Not applicableLooking for participantsNCT05466786
What this trial is testing

Distribution of the Homologous Recombination-related (HRR) Genesmutationsand HRD in Breast Cancer

Who this might be right for
Breast CancerHER2-low Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 255
Not applicableUnknownNCT05310370
What this trial is testing

HRD and Resistance to PAPPi in EOC Patients

Who this might be right for
Epithelial Ovarian CancerHomologous Recombination DeficiencyHomologous Recombination Repair Gene Mutation+4 more
Lei Li 400
Not applicableUnknownNCT04651933
What this trial is testing

A Training Set for the HRD Model in EOC

Who this might be right for
Epithelial Ovarian CancerBRCA MutationLoss of Heterozygosity+3 more
Lei Li 200
Testing effectiveness (Phase 2)Looking for participantsNCT07446855
What this trial is testing

Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours

Who this might be right for
Solid Tumours
AstraZeneca 180
Early research (Phase 1)Looking for participantsNCT06545942
What this trial is testing

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Solid TumorMetastatic Solid TumorProstate Cancer+4 more
MOMA Therapeutics 220
Not applicableUnknownNCT05255861
What this trial is testing

An Exploratory Study of HRD Score in Chinese Ovarian Cancer Patients Benefiting From PARP Inhibitor Targeted Therapy

Who this might be right for
Ovarian Cancer
Xin Wu 300
Testing effectiveness (Phase 2)Study completedNCT03274661
What this trial is testing

Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors

Who this might be right for
Solid Tumor, Adult
Baptist Health South Florida 52
Not applicableStudy completedNCT04991051
What this trial is testing

Study to Determine the Prevalence of Homologous Recombination Deficiency Among Women With Newly Diagnosed, High-grade, Serous or Endometrioid Ovarian, Primary Peritoneal, and/or Fallopian Tube Cancer

Who this might be right for
Fallopian Tube Cancer
AstraZeneca 605
Testing effectiveness (Phase 2)WithdrawnNCT03044795
What this trial is testing

Response to PARP Inhibitor Predicted by the RAD51 Assay

Who this might be right for
Cancer
University Medical Center Groningen
Not applicableLooking for participantsNCT05965557
What this trial is testing

Exploration of Predictive Markers of Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
Geneplus-Beijing Co. Ltd. 100
Testing effectiveness (Phase 2)Study completedNCT00753545
What this trial is testing

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

Who this might be right for
Ovarian Cancer
AstraZeneca 265
Large-scale testing (Phase 3)Active Not RecruitingNCT01646034
What this trial is testing

High Dose Chemotherapy in Oligo-metastatic Homologous Recombination Deficient Breast Cancer

Who this might be right for
Breast Cancer
The Netherlands Cancer Institute 74
Testing effectiveness (Phase 2)Looking for participantsNCT04515836
What this trial is testing

Olaparib in Patients With HRD Malignant Mesothelioma

Who this might be right for
MesotheliomaHomologous Recombination Deficiency
University of Chicago 56
Large-scale testing (Phase 3)Study completedNCT02975934
What this trial is testing

Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
pharmaand GmbH 405
Testing effectiveness (Phase 2)Ended earlyNCT04951492
What this trial is testing

Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma

Who this might be right for
Castration-Resistant Prostate CarcinomaProstate Adenocarcinoma
University of Washington 2
Testing effectiveness (Phase 2)Looking for participantsNCT04503265
What this trial is testing

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

Who this might be right for
Advanced Malignant NeoplasmBreast CancerOvarian Cancer+3 more
AtlasMedx, Incorporated 122
Testing effectiveness (Phase 2)Study completedNCT01891344
What this trial is testing

Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)

Who this might be right for
Ovarian CancerEpithelial Ovarian CancerFallopian Tube Cancer+1 more
pharmaand GmbH 491
Next Page